Company intelligence / Profile preview

Acorn Capital Advisors

U.S.

Ownership: Private
Development stage: Other

Overview

Acorn Capital Advisors, LLC is a U.S.-based investment firm with a current portfolio value of ~$185M, focusing on biotech, pharma, and healthcare companies primarily at pre-commercial and clinical stages, with an emphasis on oncology, rare diseases, and innovative therapies.

Therapeutic areas: OncologyNeurologyRare Diseases
Modalities: Small moleculeMonoclonal antibodyBiologicGene therapyOncolytic virus therapy
Industry: Investors

Partnerships

Indirect via investee companies

Beyond the preview

Go deeper on Acorn Capital Advisors.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acorn Capital Advisors.

Explore the full profile